<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285179</url>
  </required_header>
  <id_info>
    <org_study_id>M14POS</org_study_id>
    <nct_id>NCT02285179</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen</brief_title>
  <acronym>Poseidon</acronym>
  <official_title>Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EurocanPlatform</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rather</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a phase 1 dose escalation study followed by a randomised phase II
      study. The study will be performed in three different centres: Addenbrooke &amp; Cambridge
      university (Cambridge, UK), Netherlands Cancer Institute Amsterdam), and Vall d'Hebron
      Hospital (Barcelona, Spain).

      Three to six patients will be followed for one completed cycle of therapy (28 days) and
      subsequent enrolment of new cohorts will be based on the safety assessment in that first
      cycle and the documentation of dose limiting toxicities. To determine the safety and efficacy
      of tamoxifen in combination with the isoform selective Pi3K inhibitor GDC-0032 compared with
      tamoxifen alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the recommended phase II dose (RPTD) of GDC-0032 in combination with tamoxifen
      in hormone receptor positive, HER2 negative metastatic breast cancer patients who have
      progressed after prior endocrine treatment .Description of toxicity profile, severity and
      frequency of adverse events (observed with the combination of GDC-0032 and tamoxifen To
      evaluate the safety and tolerability of GDC-0032 in combination with tamoxifen, recording
      adverse events using CTCAE v. 4.0 criteria To describe the pharmacokinetics of GDC-0032 in
      combination with tamoxifen To investigate the possibility of major drug-drug interactions
      (PK) To obtain proof of target inhibition by selected pharmacodynamic measurements To look
      for preliminary evidence of anti-tumour activity To assess the status of potential biomarkers
      for drug response like PIK3CA gene mutations, relevant proteins and phospho-proteins in the
      PI3K pathway, circulating tumour DNA (ct-DNA) To assess germline DNA sequence for
      pharmacogenetics studies
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with MTD toxicity</measure>
    <time_frame>4 weeks</time_frame>
    <description>MTD toxicity will be assessed in the first 28 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Number of patients with adverse events</measure>
    <time_frame>2 year</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Number of patients with germline DNA sequence</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with germline DNA sequence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Number of patients with a response to protocol treatment</measure>
    <time_frame>2 year</time_frame>
    <description>Number of patients with a response to protocol treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>tamoxifen and GDC-0032</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg tamoxifen QD and 4 MG GDC-0032 QOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tamoxifen and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg tamoxifen QD and placebo QOD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0032</intervention_name>
    <description>Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd</description>
    <arm_group_label>tamoxifen and GDC-0032</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>daily dose of 20 mg</description>
    <arm_group_label>tamoxifen and GDC-0032</arm_group_label>
    <arm_group_label>tamoxifen and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Minimum age for inclusion 18 years

          -  The patient has a WHO performance status ≤ 2

          -  Premenopausal and postmenopausal female breast cancer patient with histological proven
             ER and/or PR positive*, HER2 negative breast cancer (based on the most recent
             assessment of ER and PR status from primary breast cancer or from recurrent or
             metastatic disease). If a patient is premenopausal by clinical and analytical
             assessment (defined as having premenopausal follicle stimulating hormone (FSH) and/or
             plasma estradiol levels), she should also receive a LHRH agonist.

          -  The patient's breast cancer must be negative for HER2 over-expression by IHC (IHC
             score ≤1+) or for HER2 gene amplification by FISH or CISH or SISH

          -  Patients must have either measurable or evaluable disease by RECIST criteria version
             1.1.

          -  The patient has recurrent or metastatic breast cancer that is refractory to an
             endocrine therapy defined as the occurrence of either of the following while the
             patient is on endocrine therapy:

          -  Disease progression of locally advanced or metastatic breast cancer

          -  Disease recurrence of early stage breast cancer (i.e., recurrence while receiving
             adjuvant treatment with endocrine therapy)

          -  Availability of a representative tumour tissue specimen:

          -  If a patient is currently receiving bisphosphonates, the patient must have received
             the bisphosphonates for at least 1 month before starting study treatment.

          -  The patient has adequate organ and marrow function, as defined in protocol.

          -  The patient has no other diagnosis of malignancy or evidence of other malignancy for 2
             years before screening for this study (except non-melanoma skin cancer or in situ
             carcinoma of the cervix).

          -  Life expectancy ≥ 12 weeks.

          -  Fasting glucose ≤ 120 mg/dL (=6.66 mmol/L) and HbA1c ≤ ULN.

        exclusion criteria:

          -  The following restrictions on prior anticancer therapy apply;

          -  Endocrine therapies or small molecule targeted (non-cytotoxic) inhibitors within 2
             weeks or 5 half-lives of the compound or active metabolites, whichever is longer,
             before the first dose of the study treatment are not allowed

             --No more than 5 prior chemotherapeutic regimens for metastatic breast cancer

          -  Radiation therapy within 2 weeks before the first dose of study treatment, unless of
             palliative intent, not compromising bone marrow function

          -  Cytotoxic chemotherapy within 3 weeks, or nitrosoureas or mitomycin C within 6 weeks
             before the first dose of the study treatment

          -  Antibody therapy within 4 weeks before the first dose of the study treatment

          -  Major surgery or not recovered from major surgery, within 4 weeks before the first
             dose of study treatment

          -  Other malignancy with the exclusion of carcinoma in situ.

          -  The patient has not recovered from toxicity due to prior therapy to grade ≤1 or to
             pre-therapy baseline. Patients with grade 2 peripheral neuropathy or grade 2 alopecia
             related to prior therapies are eligible

          -  The patient has untreated, symptomatic, or progressive brain metastases. -The patient
             has a history of thrombo-embolic disease or is currently receiving anticoagulation
             with therapeutic doses of warfarin.

          -  The patient has prothrombin time/ International Normalized Ratio (PT/ INR) or partial
             thromboplastin time (PTT) test results at screening that are above 1.3 x the
             laboratory upper limit of normal.

          -  Patients with a history of Crohn's disease or ulcerative colitis or other forms of
             autoimmune colitis

          -  The patient has uncontrolled significant intercurrent illness

          -  History of clinically significant cardiac or pulmonary dysfunction-The patient has a
             type 1 or 2 diabetes requiring daily anti‑hyperglycemic medication

          -  Corticosteroid use equivalent to more than 10mg prednisone daily

          -  The patient is known to be positive for the human immunodeficiency virus (HIV).

          -  The patient has a previously identified allergy or hypersensitivity to components of
             the study treatment formulation(s).

          -  The patients is unable or unwilling to abide by the study protocol or cooperate fully
             with the investigator or designee

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine C. Linn, prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Baird, dr</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Linn, MD, PhD</last_name>
    <phone>003120512</phone>
    <phone_ext>9111</phone_ext>
    <email>s.linn@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annelot van Rossum, phd</last_name>
    <phone>003120512</phone>
    <phone_ext>2004</phone_ext>
    <email>a.v.rossum@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mahasti Saghatchian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine C Linn, MD</last_name>
      <phone>+3120512</phone>
      <phone_ext>2951</phone_ext>
      <email>s.linn@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Annelot van Rossum, PhD</last_name>
      <phone>+3120512</phone>
      <phone_ext>2004</phone_ext>
      <email>a.v.rossum@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine C Linn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Beelen, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>K. Beelen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medisch Centrum</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Oosterkamp, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>R. Oosterkamp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Imholz, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>A. Imholz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Groep Twente</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E. Siemerink, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>E. Siemerink, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. de Boer, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>M. de Boer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Margeli Vila, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>M. Margeli Vila, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital/VHIO</name>
      <address>
        <city>Barcelona</city>
        <zip>080035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mafalda AM Oliviera, MD</last_name>
      <email>moliveira@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Garcia Corbacho, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>J. Garcia Corbacho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital ICO-Hospitalet (Bellvitge)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Pernas, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>S. Pernas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Morales Murillo, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>S. Morales Murillo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Amillano, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>K. Amillano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard D Baird, MA MRCP PhD</last_name>
      <phone>+44122376</phone>
      <phone_ext>8434</phone_ext>
      <email>rdb39@medschl.cam.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GDC-0032</keyword>
  <keyword>Pi3K inhibitor</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>hormone receptor positive</keyword>
  <keyword>RECIST</keyword>
  <keyword>pharmacodynamic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

